InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,174.70
(
-0.25%
)
US TECH 100
17,519.20
(
-0.53%
)
Dow Jones
38,871.78
(
-0.03%
)
Brent Oil
82.32
(
-0.66%
)
Bitcoin
61,922.38
(
-0.66%
)
Post# of 67
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

flemsnopes

Send PM Follow Ignore
Followers 32
Posts 4083
Boards Moderated 1
Alias Born 06/08/2003

flemsnopes

Re: None

Wednesday, 03/07/2012 7:28:59 AM

Wednesday, March 07, 2012 7:28:59 AM

Post# of 67
This below referenced study from 2008 with positive results, using bexarotene as a treatment for schizophrenia, seems to support a strong argument for fast track approval for Alzheimer's. Such news, along with clarification from Eisai about their business plan for this product, should bring some new attention to ESALY.

Bexarotene as Add-On to Antipsychotic Treatment in Schizophrenia Patients: A Pilot Open-Label Trial

http://journals.lww.com/clinicalneuropharm/Abstract/2008/01000/Bexarotene_as_Add_On_to_Antipsychotic_Treatment_in.4.aspx

I am only expressing my personal opinions or repeating public information from SEC filings or media outlets-which may or may not be correct. Do your own investigating before investing!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

Start posting your company's news
Only $200 per official company press release!